2.51 USD
▼-0.30-10.68%
盘后 2.66 +5.98%
2026-11-20
市值
$3.37M
市盈率
—
EPS
-18.06
股息率
—
52 周区间
2.40 – 141.50
成交量
61.86K
Beta
0.78
目标价
—
52W 低 2.4052W 高 141.50
价格走势
公司简介
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.